Results 171 to 180 of about 32,846 (250)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics. [PDF]

PLoS One
AlTaib HN, AlAqeel R, Arafat AA, Kunnathodi F, AlShaikh A, AlOtaibi HF.   +5 more
europepmc   +1 more source

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

Plant Biotechnology Journal, EarlyView.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source

Algorithm-Based Common Microcirculatory Framework for Monitoring and Visualizing the Integrated Pancreatic Microcirculation in Type 2 Diabetes Mellitus Mice. [PDF]

J Diabetes
Li Y, Wang Y, Wang B, Liu W, Xu M, Zhang X, Liu X, Ling H, Zhang X, Liu M, Xiu R.   +10 more
europepmc   +1 more source

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance ...
Nai Lee, Yun Kim
wiley   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić, Almir Fajkić, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia, Donatella Verbanac, Bojan Jelaković   +7 more
wiley   +1 more source

Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. [PDF]

Hum Reprod Open
Hviid KVR, Banasik K, Mortensen LH, Madsbad S, Strandberg-Larsen K, Geiker NRW, Westergaard D, Nielsen HS.   +7 more
europepmc   +1 more source

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: Insights from the FIGHT trial [PDF]

, 2018
Ambrosy, Andrew P, Borlaug, Barry A, Cooper, Lauren B, DeVore, Adam D, Felker, Gary Michael, Groake, John D, Hernandez, Adrian F, Lala, Anuradha, Margulies, Kenneth B, McNulty, Steven E, Mentz, Robert J, Sharma, Abhinav, Vader, Justin, Velazquez, Eric J   +13 more
core   +1 more source

Impact of and Comparative Outcomes for Digital and In‐Person Interventions for Complex Obesity in a Diverse Urban Population

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
The Southeast London Healthy Living Programme is a multi‐component, multi‐disciplinary Tier 3 obesity management service with virtual and face‐to‐face service delivery models. It offers two treatment streams, a behavioural weight management programme, Balance, and a total meal replacement plus a behavioural weight management programme, Kickstart. Among
Majella O'Keeffe, Emiliano Pena‐Altamira, Sumaya Shuriye, Danielle Dunk, Oliver Canfell, Rhys White, Alastair Duncan   +6 more
wiley   +1 more source

GLP-1 RAs for Treating Metabolic Dysfunction-Associated Steatosis Liver Disease: From GLP-1 Discovery to FDA Approval: A Comprehensive Narrative Review. [PDF]

Pharmaceuticals (Basel)
Khalifa O, Arredouani A.
europepmc   +1 more source